pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Opzelura · news · pharmadog
← back to Opzelura
News mentioning Opzelura
20
stories
3d
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
biopharma dive
14d
Alethio raises $90M to target rare blood cancers
biopharma dive
17d
Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft
biospace
17d
Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned merger
fiercebiotech
22d
Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid
fiercebiotech
25d
ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
fiercebiotech
Oct 19, 26
Merck KGaA bets on RNAi with $1.3B Silence buyout
biopharma dive
Sep 1, 26
Mid-cap biotechs join Trump’s latest round of drug pricing deals
biopharma dive
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Aug 31, 26
FDA OKs Takeda, Protagonist drug for rare blood cancer
biopharma dive
Jul 29, 26
Incyte cuts early-stage cancer drug to focus on next-gen programs
biospace
Jul 28, 26
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
Jul 16, 26
Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
fiercebiotech
Jun 26, 26
On second try, Acadia drug gets nod from European regulators
biopharma dive
Jun 15, 26
Lilly scores early positive data for new JAK drug
biopharma dive
Jun 8, 26
Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
endpoints
Jun 8, 26
Incyte to buy blood disorder drug in possibly $2B deal
biopharma dive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 5, 26
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
onclive
Apr 27, 26
Lilly to buy startup Ajax in bid for a better JAK drug
biopharma dive